Dyskinesias and their treatment with essential fatty acids: A review

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 55, Issue 1-2, 1996, Pages 89-94

  Vaddadi, Krishna ^a  

^a MAROONDAH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESSENTIAL FATTY ACID;

CONFERENCE PAPER; DIET SUPPLEMENTATION; DYSKINESIA; HUMAN; HUNTINGTON CHOREA; NONHUMAN; PRIORITY JOURNAL; TARDIVE DYSKINESIA;

EID: 0029767060     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-3278(96)90151-9     Document Type: Conference Paper

References (44)

1. Holman R. T. Essential fatty acids. In: Holman R. T., ed. Progress in the Chemistry of Fats and other Lipids. New York: Pergamon Press, 1966: 275-348.
2. Horrobin D. F. Prostaglandins, essential fatty acids and psychiatric disorders: a background review. In: Horrobin D. F., ed. Clinical Uses of Essential Fatty Acids. Montreal: Aden Press, 1982: 167-174.
3. Horrobin D. F., Manku M. S. Clinical biochemistry of essential fatty acids. In: Horrobin D. F., (ed). Omega-6 Essential Fatty acids: Pathophysilogy and Roles in Clinical Meddicine. Allan R. Liss Inc, 1990: 21-53.
4. Ordway R. W., Singer J. J., Walsh J. V. Jr. Direct regulation of channels by fatty acids. Trends Neurosci 1991; 14: 96-100.
5. Halliwell B., Gutteridge J. M. C. Free Radicals in Biology and Medicine, 2nd edn. 1989: 236-265.
6. Euvard C., Oberlander C., Boiddier J. R. Antidopaminergic effect of estrogens at the striatal lavel. J Pharmacol Exp Ther 1980; 214: 179.
7. Van Hartesveldt C., Joyce J. N. Effects of estrogen on the basal gannlia. Neurosci Biobehav Rev 1986; 10: 1.
8. Nunez E. A., Haourigui M., Martin M. E., Benassayag C. Fatty acids and steroid hormone action. Prostaglandins Leukot Essent Fatty Acids 1995; 52: 185-190.
9. Coy J. T. An animal model for Huntington's disease. Biol Psych 1979; 14: 251.
10. DiFiglia M. Excitoxic injury of the neostriatum: a model for Huntington's disease. Trends Neurosci 1990; 13: 286.
11. McGeer E. G., McGeer P. L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976; 263: 517.
12. Abdulla Y. H., Hamadah K. Effects of ADP on PGE formation in blood platelets from patents with depression, mania and schizophrenia. Br J Psych 1975; 127: 591-595.
13. Feigin A., Kieburzt K., Shoulson I. Treatment of Huntington's disease and other choreic disorders. In: Treatment of Movement Disorders. Philadelpbin, J. B. Lippincott Co.: 337-364.
14. Horrobin D. F. Schizophrenia as a prostaglandin deficiency disease. Lancet 1977; 1: 936-937.
15. Kaiya H. Prostsglandin E, treatment of schizophrenia. Biol Psych 1984; 19: 457-462.
16. Sinclair A. J., Burnett A. H., Lunee J. Free radicals and antioxidant systems in health and disease. Br J Hosp Med 1990; 43: 334-244.
17. Vaddadi K. S., Guleard C. J., Mindeham R. H. S., Butler R. A controlled trial of prostaglandin E, precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacology 1986; 88: 362-367
18. Stevens J. D. The distribution of the phospholipid fractions in the red cell membrane of schizophrenics. Schizophrenia Bull 1976; 60-61.
19. Sengupta N., Datta S. C., Sengupta D. Platelet and erythrocyte membrane lipid and phospholipid patterns in different types of mental patients. Biochem Med 1981; 25: 267-275.
20. Vaddadi K. S. Penicillin and essential fatty acid supplementation in schizophrenia. Prostaglandins Med 1979; 12: 77-80.
21. Chouinard G., Horrobin D. F., Annable L. An antipschotic effect of penicillin in schizophrenia. IRCS Med Sci 1978; 6: 187.
22. Kane J. M., Woerner M., Liberman J., Kinnon B. Tardive dyskinesia. In: Jeste D. V. and Wyatt R. J., eds. Neuropsychiatric Movement Disorders, Washington: American Psychiatric Press, Inc, 1984: 98-118.
23. Lohr J. B., Cadet J. L., Lohr M., Jeste D. V., Wyatt R. J. Alpha-tocopherol in tardive dyskinesia. Lancet 1987; 1: 913-914.
24. Lohr J. B. Oxygen radicals and neuropsychiatric illness. Arch Gen Psychiatry 1991; 48: 1097-1106.
25. McCreadiadie R. G., MacDonald E., Wiles D., Campbell G., Patterson J. R. The Nithdale Schizophrenia Surveys. XIV: Plasma lipid peroxide and serum vitamin E levels in patints with and without tardive dyskinesia, and in nomal subjects. Br J Psych 1995; 167: 610-617
26. Costall B., Naylor R. J., Owen R. T. Investigations into the nature of peri-oral movements induced by 2-[N, N-dipropyl] amino-5,6-dihydroxytetralin. Eur J Pharmacol 1977; 45: 357-367.
27. Nohria V., Vaddadi K. S. Tardive dyskinesia and essential fatty acids: An animal model study In Horrobin D. F., eds. Clinical uses of essential fatty acids 1982; 199-204.
28. Costal B., Kelly M., Naylor R. J. The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent. Br J Pharmacol 1984; 83: 773-740.
29. Yao J. K., Van-Kammen D. P., Gurklis J. Red blood cell membrane dynamics in schizophrenia III Correlation of fatty acid abnormalities with clinical measures. Schizophr Res 1994; 13: 227-232.
30. Vaddadi K. S., Courney P., Gilleard C. J., Manku M. S., Horrobin D. F. A double blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res 27: 313-323.
31. Wolkin A., Jordan B., Peselow E., Rubinstein M., Rotrosen J. Essential fatty acid supplementation in tardive dyskinesia 1986; 143: 912-914.
32. Davidson B., Kurstjens N. P., Patton J., Cantrill R. C. Essential fatty acdis modulate apomorphine activity at receptors in cat caudate slices. Eur J Pharmacol 1988; 149: 317-322.
33. Vaddadi K. S., Gilleard C. J., Soosai E., Polonowita A. K., Gibson R. A., Burrows G. Schizophrenia, tardive dyskinesia and essential fatty acids (Accepted for publication in Schizophrenia Research).
34. Kanof P. D., Davidson M., Johns C. A., Mohs R. C., Davis K. L. Clinical correlates of platelet prostaglandin reptor subsensitivityce in schizophrenia. Am J Psychol 1987; 144: 1556-1560.
35. Houtia N. E., Maziere J. C., Maziere C., Auclair M. Phenothiazines inhibit cholesteryl ester formation in J774 monocyte like cells. Biol J Clin Chem Clin Biochem 1988; 26: 673-678.
36. Sengupta N., Datta S. C., Sengupta D. Platelet and erythrocyte membrane lipid and phospholipid pattern in different types of mental patients Biochem Med 25: 267-275.
37. Horrobin D. F., Manku M. S., Morse-Fisher N. et al Essential fatty acids in plasma phosphlipida in schizophrenics. Biol Psychol 1989; 25: 562-568.
38. Kaiya H., Horrobin D. F., Manku M. S., Morese-Fischer N. Essential and other fatty acids in plasma from schizophrenics and nomal individuals from Japun. Biol Psychol 1991; 30: 357-362.
39. Glen A. I. M., Glen E. M. T., Skinner F. K., Horrobin D. F. Essential fatty acids in schizophrenia and the effect of antipsychotic drugs on cell membranes. J Psychopharmacol Abstract book BAP/EBPS meeting 1992; 101: A26.
40. Horrobin D. F., Manku M. S., Hillman H., Iain A., Glen M. Fatty acid levels in the brains of schizophrenics and normal controls. Biol Psychol 1991; 30: 795-805.
41. Meyers R. H., Sax D. S., Koroshetz W. J. Factors associated with slow disease progression in Huntington's disease. Arch Neurol 1991; 48: 800.
42. Nunez E. A. Fatty acids and cell signalling. Prostaglandins Leukot Essent Fatty Acids 1993; 48: 1-122.
43. Miller B., Sarantis M., Traynelis S. F., Atwell D. Potentiation of NMDE receptor currents by arachidonic acid. Nature 1992; 355: 722-725.
44. Britton J. W., Uitti R. J., Ahlskog J. E., Robinson R. G., Kremer B., Hayden M. R. Hereditary late-onset chorea without significant dementia: genetic evidence for substantial phenotypic variation in Huntington's disease. Neurology 1995; 45: 443-447.